期刊文献+

鸡CTLA-4蛋白在昆虫细胞中的表达及其单克隆抗体的制备

Expression of Chicken CTLA-4 Protein in Insect Cells and the Preparation of Its Monoclonal Antibody
下载PDF
导出
摘要 旨在制备鸡细胞毒性T淋巴细胞相关抗原4(CTLA-4)的特异性单克隆抗体,为家禽免疫检查点和疫苗研发提供有益制剂。利用杆状病毒表达系统体外表达鸡的CTLA-4蛋白,以其为免疫原免疫8周龄Balb/c小鼠,经B淋巴细胞融合技术制备、筛选出针对鸡CTLA-4蛋白的单克隆抗体。通过间接免疫荧光、蛋白免疫印迹、流式细胞术等方法分析抗CTLA-4单克隆抗体的生物学特性。结果显示:构建了在Sf9昆虫细胞中表达CTLA-4蛋白的重组杆状病毒,成功筛选出3株能稳定分泌抗鸡CTLA-4蛋白的单克隆抗体,分别命名为:mAb-CTLA4-3D7、mAb-CTLA4-5A4、mAb-CTLA4-6A12。亚类鉴定表明,mAb-CTLA4-3D7为IgG2a, Lambda链;mAb-CTLA4-5A4为IgG3,Kappa链;mAb-CTLA4-6A12为IgG2a, Kappa链。3株单克隆抗体均能与转染真核表达质粒pCAGGS-CTLA-4-Flag的DF-1细胞和感染重组杆状病毒rBac-CTLA-4的Sf9昆虫细胞反应。单克隆抗体mAb-CTLA4-3D7与鸡的PBMC有较好的结合活性,且能与CD3+T淋巴细胞结合,结合率约为16%。本研究首次成功制备了抗鸡CTLA-4蛋白的单克隆抗体,并分析了其反应活性及生物学特性,为免疫检查点在禽病的发病机制、信号通路、疫苗研发等研究领域提供了材料。 In order The aim of this study was to prepare monoclonal antibody specific to chicken CTLA-4,and provide useful tools for research on the poultry immune checkpoint and vaccine development.Baculovirus expression system was used to express chicken CTLA-4 protein in vitro.The monoclonal antibodies against chicken CTLA-4 protein were prepared by fusion between SP2/0 cells and spleen cells from the 8-week-old Balb/c mice immunized with the expressed chicken CTLA-4 protein.The charcterization of monoclonal antibodies were analyzed by indirect immunofluorescence,Western blot and flow cytometry.The recombinant baculovirus expressing CTLA-4 protein in Sf9 insect cells was constructed.Three monoclonal antibodies against chicken CTLA-4 protein were successfully obtained,named as mAb-CTLA4-3D7,mAb-CTLA4-5A4 and mAb-CTLA4-6A12.The subclass of mAb-CTLA4-3D7 was IgG2a and type Lambda;The subclass of mAb-CTLA4-5A4 was IgG3 and type Kappa;The subclass of mAb-CTLA4-6A12 was IgG2a and type Kappa.All three monoclonal antibodies could react with DF-1 cells transfected with pCAGGS-CTLA-4-Flag and Sf9 insect cells infected with rBac-CTLA-4.Among them,mAb-CTLA4-3D7 had a good binding activity with chicken PBMC and could react to CD3+T lymphocytes,with the binding rate of about 16%.In this study,monoclonal antibodies against chicken CTLA-4 protein were successfully developed,and their reactivity and biological characteristics were analyzed,which provided a reference for immune checkpoints in the pathogenesis,signaling pathways,vaccine development and other research fields of avian diseases.
作者 刘青 吴少鹏 石彬 邵红霞 钱琨 叶建强 秦爱建 LIU Qing;WU Shaopeng;SHI Bin;SHAO Hongxia;QIAN Kun;YE Jianqiang;QIN Aijian(Ministry of Education Key Laboratory for Avian Preventive Medicine,College of Veterinary Medicine,Yangzhou University,Yangzhou 225009,China;Jiangsu Province Key Laboratory of Preventive Veterinary Medicine,College of Veterinary Medicine,Yangzhou University,Yangzhou 225009,China;Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses,College of Veterinary Medicine,Yangzhou University,Yangzhou 225009,China;Joint International Research Laboratory of Agriculture and Agri-Product Safety,the Ministry of Education of China,Yangzhou University,Yangzhou 225009,China)
出处 《畜牧兽医学报》 CAS CSCD 北大核心 2023年第6期2596-2604,共9页 ACTA VETERINARIA ET ZOOTECHNICA SINICA
基金 国家自然科学基金(31972717)。
关键词 鸡CTLA-4 杆状病毒 单克隆抗体 生物学特性 chicken CTLA-4 baculovirus monoclonal antibody biological characteristics
  • 相关文献

参考文献2

二级参考文献45

  • 1Chen L. Co-inhibitory molecules of the B7-CD28 family in thecontrol of T cell immunity [ J ] . Nat Rev Immunol,2004,4(5):336 -347.
  • 2Carreno BM,Bennett F, Chau TA. CTLA-4( CD152) can inhibitT cell activation by tow different mechanisms depending on itslevel of cell surface expression [ J ]. J Immunol,2000,165.3) :1352.
  • 3Wells AD,Walsh MC,Bluestone JA,et al. Signaling throughCD28 and CTLA-4 controls two distinct forms of Tcell anergy[J]. J Clin Invest,2001,108(6) :895 -903.
  • 4Peggs KS, Quezada SA, Korman AJ,et al. Allison JP: Principlesand use of anti-CTLA4 antibody in human cancer immunotherapy[J]. Curr Opin Immunol,2006, 18(2):206 -213.
  • 5Wolchok JD, Neyns B,Linette G,et al. Ipilimumab monotherapyin patients with pretreated advanced melanoma : a randomised,double-blind,multicentre,phase 2,dose-ranging study [ J ].Lancet Oncol,2010,11 (2) :155 -164.
  • 6Hodi FS,O,Day SJ,McDermott DF,et al. Improved survival withipilimumab in patients with metastatic melanoma [ J]. N Engl JMed, 2010,363(8) :711 -723.
  • 7Salgaller M, Marincola F, Cormier J,et al. Immunization againstepitopes in the human melanoma antigen gplOO following patientimmunization with synthetic peptides[ J]. Cancer Res, 1996,56(20):4749 -4757.
  • 8Kom EL, Liu PY,Lee SJ,et al. Meta-analysis of phase II coop-erative group trials in metastatic stage IV melanoma to determineprogression-free and overall survival benchmarks for future phaseII trials[J]. J Clin Oncol, 2008,26(4) :527 -534.
  • 9Robert C, Thomas L,Bondarenko I,et al. Ipilimumab plus dacar-bazine for previously untreated metastatic melanoma[ J]. N EnglJ Med,2011,364(26) :2517 -2526.
  • 10O,Day SJ, Hamid 0,Urba WJ. Targeting cytotoxic T-lymphocyteantigen-4 ( CTLA-4 ) : a novel strategy for the treatment of melano-ma and other malignancies[ J]. Cancer, 2007 ,110( 12) :2614 -2627.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部